TechFlow news, June 20 — According to PRNewswire, Parataxis Holdings LLC has signed a definitive agreement with Bridge Biotherapeutics through Parataxis Korea Fund I LLC and its affiliates to invest 25 billion Korean won for controlling interest. Upon completion of the transaction, Bridge Biotherapeutics will be renamed Parataxis Korea and will continue to be listed on Korea's KOSDAQ.
Andrew Kim said they were inspired by growing interest from companies such as Strategy in the U.S. and Metaplanet in Japan regarding Bitcoin treasury strategies, indicating increasing global institutional interest in this space, and that South Korea is an important market in the evolution of Bitcoin adoption.
Add to Favorites
Share to Social Media
